Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EBIT (2022 - 2026)

Zentalis Pharmaceuticals has reported EBIT over the past 5 years, most recently at -$37.9 million for Q1 2026.

  • For Q1 2026, EBIT rose 17.03% year-over-year to -$37.9 million; the TTM value through Mar 2026 reached -$145.0 million, up 31.6%, while the annual FY2025 figure was -$152.8 million, 20.08% up from the prior year.
  • EBIT for Q1 2026 was -$37.9 million at Zentalis Pharmaceuticals, down from -$37.4 million in the prior quarter.
  • Over five years, EBIT peaked at -$24.8 million in Q1 2024 and troughed at -$103.9 million in Q2 2023.
  • A 5-year average of -$53.5 million and a median of -$51.8 million in 2022 define the central range for EBIT.
  • Biggest five-year swings in EBIT: skyrocketed 61.87% in 2024 and later tumbled 84.22% in 2025.
  • Year by year, EBIT stood at -$51.8 million in 2022, then plummeted by 31.24% to -$67.9 million in 2023, then increased by 26.61% to -$49.8 million in 2024, then increased by 24.99% to -$37.4 million in 2025, then dropped by 1.24% to -$37.9 million in 2026.
  • Business Quant data shows EBIT for ZNTL at -$37.9 million in Q1 2026, -$37.4 million in Q4 2025, and -$33.7 million in Q3 2025.